Ubs Group Ag Innate Pharma Sa Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Innate Pharma Sa stock. As of the latest transaction made, Ubs Group Ag holds 297 shares of IPHA stock, worth $668. This represents 0.0% of its overall portfolio holdings.

Number of Shares

297

Previous 210 41.43%

Holding current value

$668

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.94 - $3.0 $168 - $261	87 Added 41.43%	297 $0
Q1 2024 May 13, 2024	BUY	$2.37 - $2.93 $151 - $187	64 Added 43.84%	210 $0
Q2 2023 Aug 11, 2023	SELL	$2.78 - $3.5 $3,094 - $3,895	-1,113 Reduced 88.4%	146 $0
Q1 2023 May 12, 2023	BUY	$2.67 - $3.86 $2,971 - $4,296	1,113 Added 762.33%	1,259 $3,000
Q4 2022 Feb 08, 2023	SELL	$1.9 - $3.73 $8,282 - $16,259	-4,359 Reduced 96.76%	146 $0
Q3 2022 Nov 10, 2022	BUY	$2.0 - $3.2 $3,098 - $4,956	1,549 Added 52.4%	4,505 $9,000
Q2 2022 Aug 10, 2022	BUY	$2.0 - $3.55 $5,912 - $10,493	2,956 New	2,956 $8,000

Others Institutions Holding IPHA

# of Institutions

Shares Held

242K

Call Options Held

Put Options Held

View Full List

About Innate Pharma SA

Ticker IPHA
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,893,000
Market Cap $180M
Description
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...

More about IPHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account